Everolimus Pellets – Available as Nanoparticles with 2.5%, 5% & 10% Strengths.

  • MKPPL is the first to come up with pellet based approach for immune suppressants.
  • Facilitates direct filling into capsules and can be easily employed in tableting. Nano particles can be effectively used for manufacturing of ointments (Tacrolimus) and solutions (Everolimus).
  • MKPPL pellet advantages includes using a micro emulsion technology. No cyclization of the drug, hence less delta lactones formation.
  • Coated pellets, hence the formulator does not require a contained facility for finished formulation.
  • Offer complete technical package for registrations in all regulated/semi regulated markets.

Additional information

2.5%, 5%

Target Formulations

Capsules, Tablets, Suspension

Routes of administration


Documentation Available:

Technical Package

Privacy Preference Center